All stocks / CNBX
CNBX Pharmaceuticals Inc. CNBX
CNBX Pharmaceuticals (CNBX): shares outstanding up 1636% in a year, convertible notes mentioned in an 8-K in March 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.
Market listing
- Full name
- CNBX PHARMACEUTICALS INC
- Market tier
- OTC Pink Current
- Trading status
- Active
- Last trade
- Nov 16
- Website
- www.cannabics.com
The financial report, and what it means
Annual figures to 2025-08-31- Revenue
- $0
- Net loss
- ($313,976)
It spends more than it earns
Under strainThe company lost $313,976 in the year. It reported no sales.
- Cash and cash equivalents
- $15,111
- Net cash used in operating activities
- ($171,305)
The cash could run out soon
Under strainIt had $15,111 in the bank and used about $14,275 a month. At that pace the money lasts about 1 months unless it borrows or sells more shares.
- Total assets
- $18,437
- Total liabilities
- $2,514,730
It owes more than it owns
Under strainEverything the company owns adds up to $18,437. Its debts and unpaid bills add up to $2.5 million. That is about $136.40 owed for every $1 owned.
What this adds up to
3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.
Signals
Shares outstanding rose from 92,511,352 (2025-05-31) to 1,605,768,095 (2026-06-17), up 1636%.
Rule: Shares outstanding up 20% or more in 12 months. Source record
Estimated float about 1,605,768,095 shares as of 2026-06-17: 1,605,768,095 outstanding minus 0 held by 0 reporting insider(s).
Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record
8-K filed 2026-03-17 mentions: convertible note.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
Shares outstanding
Source: SEC filingsPrice chart
Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets
Recent filings
| 2026-11-12 | SCHEDULE 13G/A | |
| 2026-10-01 | 8-K | CURRENT REPORT |
| 2026-08-14 | SCHEDULE 13G/A | |
| 2026-06-24 | 10-Q | FORM 10-Q FOR MAY 2026 |
| 2026-05-08 | SCHEDULE 13G/A | |
| 2026-04-14 | 10-Q | FORM 10-Q |
| 2026-03-17 | 8-K | FORM 8-K |
| 2026-02-05 | SCHEDULE 13G/A | |
| 2026-01-14 | 10-Q | QUARTERLY REPORT |
| 2025-12-01 | 10-K | FORM 10-K FOR AUG 2025 |
Common questions about CNBX
Does CNBX file reports with the SEC?
Yes. CNBX Pharmaceuticals files with the SEC under company number 0001343009. The most recent filing we hold is a SCHEDULE 13G/A dated 2026-11-12.
Source recordHow many CNBX shares are outstanding?
1,605,768,095 shares as of 2026-06-17, as reported to the SEC. That is up 1636% from 92,511,352 on 2025-05-31.
Source recordHas CNBX filed reports late?
We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.
Is CNBX Pharmaceuticals making money?
The company lost $313,976 in the year. It reported no sales. (Annual figures to 2025-08-31. Facts from the company's own report, not a recommendation.)
Source record